Latest Conference Articles

November 13th 2020, 6:56pm

SITC Meeting

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

November 13th 2020, 2:20pm

SITC Meeting

November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.

November 12th 2020, 10:53pm

SITC Meeting

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

November 12th 2020, 10:50pm

SITC Meeting

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

November 12th 2020, 10:47pm

SITC Meeting

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

November 12th 2020, 10:33pm

SITC Meeting

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

November 12th 2020, 10:21pm

SITC Meeting

November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.

November 12th 2020, 9:50pm

SITC Meeting

November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.

November 12th 2020, 9:50pm

SITC Meeting

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

November 12th 2020, 9:50pm

November 12, 2020 - The first-in-class, next-generation, DuoBody-PD-L1×4-1BB bispecific antibody GEN1046 demonstrated promising early activity and an acceptable safety profile in in patients with advanced solid tumors.

November 12th 2020, 9:30pm

November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager, was shown to have a feasible adverse effect profile in patients with small cell lung cancer.

November 12th 2020, 5:30pm

November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.

November 10th 2020, 9:37pm

PER® New York Lung Cancer Symposium

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

November 9th 2020, 10:57pm

PER® New York Lung Cancer Symposium

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

November 9th 2020, 10:19pm

PER® New York Lung Cancer Symposium

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

November 9th 2020, 10:09pm

International Kidney Cancer Symposium

The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.

November 9th 2020, 9:34pm

PER® New York Lung Cancer Symposium

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

November 9th 2020, 8:34pm

PER® New York Lung Cancer Symposium

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.

November 8th 2020, 4:01pm

PER® Chemotherapy Foundation Symposium (CFS)

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

November 7th 2020, 10:12pm

PER® New York Lung Cancer Symposium

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.